Autism (MIM 209850) is a pervasive developmental disorder (PDD) characterized by impairments in communication, language and reciprocal social interaction and by unusual patterns of restricted and repetitive interests or behaviors. 1 While disease susceptibility in autism is clearly attributable to genetic factors, with a heritability estimate 490%, 2 the mode of inheritance appears complex. 2, 3 Several genome-wide screens for regions conferring susceptibility to autism have now been reported. [4] [5] [6] [7] [8] [9] [10] With the exception of regions on 2q and 7q, there has been very little overlap in the highest linkage peaks reported in the different studies. These disparate findings have been interpreted as evidence that autism may involve extensive genetic heterogeneity 3 or that multiple interacting genes of weak effect contribute to susceptibility to the disorder. 9 Decreasing sample heterogeneity by segregating the samples according to clinical features has been advocated as a means for increasing the likelihood of identifying susceptibility genes in autism. 11 Identifying distinct clinical features has been facilitated by the Autism Diagnostic Interview-Revised (ADI-R) 12 and the Autism Diagnostic Observation Schedule (ADOS), 13 standardized instruments for accurately and reliably recording and quantifying historical and clinical features in autism. Subsetting by language impairment as measured on the ADI-R by onset of phrase speech after 36 months of age increased the linkage signal on chromosome 2q.
14 Analysis of a subset of families with severe obsessive-compulsive features reported in the ADI-R identified a new candidate region on chromosome 1.
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The ADI-R also records information about developmental regression, a loss of previously acquired sociocommunicative skills, which has been suggested as another means of categorizing children with autism into more homogeneous subgroups. 16 Regression is a phenomenon that occurs in 20-30% of children with autism, usually between the ages of 18 and 24 months. 17 Regression involves loss of language skills and/or loss of other socially communicative skills such as eye contact or gestures, and is rarely seen in other developmental disorders. 18 Measurable differences have been reported between children with autism with regression and children with autism without regression in the areas of cognition 19, 20 and social interaction, 21 suggesting that they are distinct subgroups. These differences may result from different etiologic pathways, but most children with autism who experience regression do not have completely normal development prior to the regressive episode. 18, 22 This presentation is more consistent with regression as a modification of the underlying disease processes in autism. In either case, children with autism and a history of regression are likely to represent a more genetically homogeneous subgroup. In the current study, we undertook analyses to locate autism susceptibility loci in families with a history of regression.
Materials and methods

Subjects
Families for this study were recruited by the Autism Genetic Resource Exchange (AGRE). 23 AGRE is a national family registry and DNA repository that was developed as a joint effort between the Cure Autism Now (CAN) Foundation and the Human Biological Data Interchange (HBDI) to facilitate genetic research and to make well-characterized families with autism widely available to investigators. 23 Thorough clinical evaluations, including the ADI-R and the ADOS, are performed on potential subjects in addition to blood draws. At the present time there are 385 multiplex families in the registry. A genome scan has been performed on 357 of these families at the Columbia Genome Center using the James Weber version 6 microsatellite marker set with additional markers selected from the Marshfield Database. Phenotypic and genotypic data for this study were downloaded from the AGRE website (www.agre.org). AGRE has Institutional Review Board Approval from Western Institutional Review Board, Inc. and the University of California, Los Angeles. The study was also approved by the Institutional Review Board of Cincinnati Children's Hospital Medical Center.
For this study, participants were considered affected with autism if they met or exceeded the standard specified algorithm cutoff scores in all three domain areas of the ADI-R and had onset of symptoms before age 36 months. They were considered affected with an autism spectrum disorder (ASD) if they met the ADI-R domain cutoffs specified by AGRE for a classification of 'Not Quite Autism'. The designation of ASD is inclusive of PDD-Not Otherwise Specified-and Asperger Syndrome as described in the Diagnostic and Statistical Manual of the American Psychiatric Association. 1 Regression status was based on the results of item 95a of the ADI-R (1995 version) in which the examiner uses information obtained during the interview to determine if developmental regression had occurred. Participants were considered to have a positive history of regression if the score on the item was 2 'definite history of regression'. They were considered to have a negative history for regression if the item was scored 0. If the item was scored 1, 'questionable history of regression', their regression status was considered as unknown for the purpose of the analyses. Families were included in the study if at least one individual in the family was affected with autism, a relative had either autism or ASD, and both had a definite history of regression. Families were excluded from the study if there was a known history of Fragile X or other chromosomal abnormality, or if monozygotic multiples were the only affected siblings.
The collection of blood specimens from affected individuals, unaffected siblings and parents, the procedures for cell transformation, polymerase chain reaction (PCR) amplification and the genotyping of 408 microsatellite markers across the genome were all carried out by AGRE and have been previously described. 7, 10 The average heterozygosity of the markers was 0.77 with an average genetic spacing of 10 cM. Biomaterial production and storage is located at the Rutgers University Cell Repository. 23 
Genotyping
In addition to analysis of existing genotypic data, the DNA specimens from the subset of families identified as having at least two relatives with a positive history for regression were acquired from the cell repository. Additional genotyping of these specimens was performed using nine microsatellite markers on chromosome 21 from the high-density ABI Prism s Linkage Mapping Set (Applied Biosystems, Foster City, CA, USA) in and around the candidate region for the regression phenotype that was identified in the analysis of the AGRE genotype data. The nine markers were amplified by multiplex PCR in two groups of compatible amplicon size/dye color combination. The 10 ml reactions each containing 50 ng of genomic DNA were performed using the Multiplex PCR Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's recommendations. After amplification, samples were electrophoresed on an ABI 3730xl DNA Analyzer. Allele scoring was performed using the GeneMapper 3.5 genotyping software (Applied Biosystems).
Statistical analysis
Multipoint linkage analyses were performed on the existing AGRE genotype data and the additional microsatellite markers with Genehunter-plus v1.2.
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Parametric multipoint LOD score analyses under dominant and recessive modes of inheritance were conducted with penetrance set at 50%. 25 Disease allele frequencies were set at 0.045 for recessive inheritance and 0.001 for dominant inheritance as derived from a population prevalence of the regression phenotype of 0.2% and assuming Hardy-Weinberg equilibrium. The phenocopy rate was arbitrarily set at 0.0001. Nonparametric analysis methods were also conducted by calculating the NPL score and Pvalue reflecting deviation from expected random sharing between affected members. To compare and plot the results of parametric and nonparametric linkage analyses together (Figure 1 ), the NPL P-value was transformed into a LOD score equivalent using the formula LOD ¼ (U
À1
(P-value)) 2 /2ln 10 where U À1 (n) is the nth percentile of the standard normal distribution. 26 All genotyped family members were included in the analyses and the affected status was defined as having a positive history for regression. Individuals not having a clear positive history for regression were considered as phenotypically unknown. Genetic distances were taken from the Marshfield comprehensive human genetic maps. 27 Marker allele frequencies were calculated from all the genotyped originals in the data set.
Simulations
All available genotypes for markers on chromosome 7 and chromosome 21 were simulated 10 000 times using the program SIMULATE developed by Terwilliger et al. 28 Each time, the simulated data set was analyzed under the same conditions as the observed data set, and at each position on the genetic map the LOD score and the NPL score for the simulated data were compared to the observed scores. The proportion of simulated data sets with scores equal to or greater than the observed data set scores is an approximation of the true empirical significance level (P-value). 29 
Results
From the AGRE database, 288 affected relative pairs (ARPs) with autism/ASD were identified, who had phenotypic and genotypic information available. There were 190 ARPs in which both relatives met ADI-R classification for autism and 98 ARPs in which at least one individual met criteria for autism and the other met criteria for ASD. Of the 288 ARPs, 151 (52%) were concordant for no history of regression (11 of these had an item score of 1 and were considered unknown). There were 32 affected sib-pairs (ASPs), one affected sib trio and one cousin pair concordant for a definite history of regression.
These 34 families were examined for evidence of linkage, using regression as the definition of phenotype. The genome scan revealed two peaks with a maximum multipoint LOD score 43.0 or NPL P-value o 10 À4 (Figure 1 ). On chromosome 7 near D7S483, a LOD score of 2.0 under the dominant mode of inheritance and an NPL score of 3.7 (P ¼ 7.9 Â 10 À5 ) were observed. On chromosome 21 near D21S1437, a LOD score of 3.4 under the dominant mode of inheritance and an NPL score of 3.0 (P ¼ 1.3 Â 10 À3 ) were observed. No other area of the genome showed a significant LOD or NPL score in this restricted data set.
As no previous report of a susceptibility region for autism existed on chromosome 21q and because the raw genotypes were not available for verification, we genotyped the nine additional microsatellite markers on 21q from a commercially available set for members of the 34 family subset (n ¼ 140). The new genotypes were analyzed independently of the AGRE genotypes for confirmation purposes, then in combination, to maximize the information and accuracy of the linkage signal by increasing marker density. Analyses were conducted using the same statistical methods as for the genome scan data.
For the independent analysis, the maximum multipoint LOD score under the dominant mode of inheritance is 2.9 and the NPL score is 3.3 (P ¼ 5.1 Â 10 À4 ) near D21S1904. Results of this analysis and analysis of the AGRE genotyping are shown in Figures 2 and 3 , along with the results of the combined analysis, in which a maximum multipoint LOD score of 3.0 was observed under the dominant mode of inheritance, with an NPL score of 3.4 (P ¼ 3.5 Â 10 À4 ) near D21S1432. On chromosome 7, the results of 10 000 simulations of the available AGRE genotypes showed that a LOD score of 2.5 and an NPL score of 3.7 were not exceeded during the analysis of any random set of genotypes. This gives an estimate of the empirical P-value for the significance of the LOD score and NPL of o 10
À4
. On chromosome 21, the 10 000 simulations of all available AGRE and independently generated genotypes led to the estimation of an empirical P-value of o 10 À4 for the LOD score since it was not exceeded by any of the analyses of simulated data, and of 3 Â 10
for the NPL score since it was exceeded three times. These estimations of empirical P-values closely match the asymptotic estimates calculated by Genehunter, given that a LOD score of 3 is equivalent to a 10 À4 P-value.
30 Figure 1 Results of parametric and nonparametric wholegenome linkage analysis in autism affected relative pairs from the AGRE data set concordant for a history of regression (n ¼ 34). Reported as LOD score for dominant mode and LOD equivalent for NPL P-value.
Discussion
In this analysis of families with a history of regression, evidence for linkage was found on 7q (NPL score of 3.7; P ¼ 7.9 Â 10 À5 ), confirming previous reports of this region as a candidate for susceptibility to autism. 6, 31, 32 In this study, we also found new evidence for linkage on 21q in autism, using history of regression as the defined phenotype. The strongest evidence for linkage was found between markers D21S1432 (16.2 Mb) and D21S1899 (18.9 Mb), a 2.7 Mb region on 21q. The NCBI build 35 (May 2004) of the human genome sequence indicates that seven known genes map to this region. Two of them, BTG3 (also known as ANA) (17.9 Mb) and CXADR (17.8 Mb) are expressed in fetal brain, 33, 34 making them likely candidates to contribute to susceptibility to autism. BTG3 is a member of a family of antiproliferative genes known to play a role in cellular differentiation 35 and potentially, apoptosis, 36 which have been implicated in the etiology of autism. 37 -39 BTG3 appears to be involved in cellular responses to oxidation-reduction changes, 34 which have also been implicated as potentially contributing to autism. 40, 41 CXADR, a member of the immunoglobulin superfamily, is a coxsackie virus and adenovirus receptor whose primary biological function is unknown. Overexpression of this gene increases susceptibility to infection by these viruses. 42 This gene would be considered a functional candidate because there is clear evidence that autism can occur following maternal infection with some viruses such as rubella 43 and speculation that exposure of the developing fetus to other viruses such as influenza may contribute to autism. 44, 45 Another gene immediately outside the D21S1432 to D21S1899 interval, which is expressed in fetal brain and is a potential candidate for susceptibility to autism, is NCAM2 (21.3 Mb) (Figure 4 ). This gene is involved in cellular adhesion and motility in the developing nervous system, 46, 47 and there is evidence that aberrant cellular migration occurs in some individuals with autism. 48 Besides BTG3 and CXADR, our 2.7 Mb region of interest also contains CHODL (gene for chondrolectin; 18.5 Mb), PRSS7 (gene for enterokinase; 18.6 Mb), and three other genes coding for hypothetical proteins.
There are several limitations to this study that result from analysis of an existing publicly available database designed to examine the genetics of autism. It is not possible to estimate the number of analyses that have been performed for different phenotypic subsets of this data set as would traditionally be performed to determine a correction for multiple testing. To minimize this impact, we have estimated the q value (false discovery rate) 49 as 0.039 for our two linkage peaks, providing an acceptable level of confidence in these findings. A second limitation is that only 28 of the 69 individuals in this data set classified as affected by the ADI-R were also evaluated with an ADOS. Given this small proportion, it is difficult to incorporate information from the ADOS into an analysis of the whole sample, so, for this study, classification of autism/ASD was based strictly on the results of the ADI-R.
In summary, we have provided evidence that loci on chromosomes 7 and 21 contribute to susceptibility to the regressive phenotype of autism. The finding of a candidate region on chromosome 21 is of particular interest given that children with trisomy 21 (Down syndrome) are 10 times more likely to have an ASD than the general population. 50 In addition, more than half of one sample of children with Down syndrome and ASD were reported to have a history of regression, 51 suggesting that it is this regressive phenotype that is associated with Down syndrome. The findings reported here represent the important first step in identifying genetic variants contributing to susceptibility to this specific phenotype of autism/ASD. Three genes that emerge as positional candidates in this newly identified region, BTG3, CXADR and NCAM2 have plausible biological mechanisms that make them likely functional candidates as well, warranting further investigation.
